In short
Clinical trials listed here include Siltuximab as part of studies mainly in small cell lung cancer and other cancer research. These trials look at safety, efficacy, survival, and response to treatment in different patient groups, including people with relapsed, limited-stage, and extensive-stage disease.
Key points
- Siltuximab appears in several clinical trials, mostly in cancer studies. The main focus is small cell lung cancer, including relapsed, limited-stage, and extensive-stage disease, plus a few studies in other advanced cancers. Most trials are Phase 2 or Phase 3, with one Phase 1/2 study. The trials are mainly looking at survival, tumor response, progression-free survival, safety, and adverse events. Some studies compare treatment combinations against placebo or standard of care. The patient groups are adults with advanced or hard-to-treat cancer, and each trial has its own rules for entry.
Trial overview
The source data shows Siltuximab in several cancer trials, mostly as part of combination studies rather than as a stand-alone study drug. These trials are mainly in small cell lung cancer, with a few studies in other advanced cancers such as metastatic prostate cancer and B-cell lymphoma.
Most of the studies are Phase 2 or Phase 3 trials, and one study is a Phase 1/2 trial. The main purpose is to compare how well the treatment works and to check safety in different patient groups.
Small cell lung cancer studies
Several trials focus on small cell lung cancer, including relapsed or refractory disease, limited-stage disease, and extensive-stage disease. “Relapsed” means the cancer came back after treatment, and “refractory” means it did not respond well to treatment.
In NCT05060016, researchers are studying tarlatamab in people with relapsed or refractory small cell lung cancer, with outcomes including objective response and treatment-emergent adverse events. The study also looks at serum concentrations of tarlatamab in part of the trial, which means the amount of drug in the blood is being measured.
NCT06745323 is a Phase 2, open-label, randomized, multicenter study in people with small cell lung cancer, and it measures confirmed complete response and partial response. “Open-label” means both the researchers and participants know which treatment is being given. “Randomized” means participants are assigned by chance to different study groups.
NCT06117774 studies tarlatamab after chemoradiotherapy in limited-stage small-cell lung cancer, which means treatment is given after chemotherapy and radiation. The main outcomes are progression-free survival and overall survival.
NCT05740566 compares tarlatamab with standard of care chemotherapy in relapsed small cell lung cancer, and the main endpoint is overall survival. This trial is designed to see whether one treatment approach helps people live longer than the usual treatment.
2024-520050-38-00 and NCT06211036 both study extensive-stage small cell lung cancer, which is a more advanced form of the disease where cancer has spread widely. These studies compare tarlatamab-based combinations against other treatment approaches and measure overall survival, with one also measuring progression-free survival.
Other cancer studies
NCT05220098 is a first-in-human Phase 1/2 study in people with unresectable locally advanced or metastatic cancer. “First-in-human” means the treatment is being studied in people for the first time. The trial focuses on safety, tolerability, dose-limiting toxicities, and finding the maximum tolerated dose and recommended Phase 2 dose.
2023-504830-23-00 is a Phase 3 study in B-cell lymphoma, comparing epcoritamab with standard of care chemotherapy and measuring overall survival and progression-free survival. The study uses Lugano criteria, which is a standard way to judge lymphoma response on scans and other tests.
NCT06691984 and 2025-520555-89-00 are Phase 3 studies in metastatic castration-resistant prostate cancer, and both compare study treatment against investigator’s choice options. Their main outcome is overall survival.
What researchers measure
The trials measure different outcomes to show whether treatment is helping and whether it is safe. Common measures include overall survival, progression-free survival, and objective response, which tells whether tumors shrink or disappear.
Some studies also measure complete response and partial response, which are more detailed ways to describe tumor improvement. Safety measures include treatment-emergent adverse events and dose-limiting toxicities, which help researchers see whether a treatment causes new health problems or too much side effect burden.
In some trials, results are checked by blinded independent central review or an independent review committee, meaning outside experts review the data without knowing which treatment was used. This helps make the results more fair and reliable.
Who may join these trials
The target populations are people with cancer that is advanced, has spread, or has come back after treatment. The trials include people with relapsed or refractory small cell lung cancer, limited-stage small-cell lung cancer, extensive-stage small cell lung cancer, unresectable locally advanced or metastatic cancer, B-cell lymphoma, and metastatic castration-resistant prostate cancer.
Each study has its own entry rules, so not every person with the listed condition can join. The study team uses those rules to decide who is eligible and to keep the trial group as similar as possible for fair comparison.
How to read the trial phases
Phase 1/2 trials usually start by checking safety, side effects, and dose, then may also look for early signs that the treatment works. This is why the first-in-human study focuses on dose-limiting toxicities and the recommended dose for later testing.
Phase 2 trials are often used to see if the treatment shows enough benefit to keep studying it, while continuing to watch safety. Phase 3 trials are larger and compare the study treatment with another treatment or placebo to see which option works better for patients.